Anticoagulant and Antiplatelet Therapies - Episode 4

What the DAPT Trial Means for Pharmacists

EP. 1: Will Warfarin Remain the Cornerstone Anticoagulant?
EP. 2: ANNEXA-R Study Shows Promise for Rivaroxaban Reversal Agent
EP. 3: DAPT Trial Touts Longer Dual Antiplatelet Duration
Now Viewing
EP. 4: What the DAPT Trial Means for Pharmacists
EP. 5: Therapy Compliance in DAPT Trial
EP. 6: Ticagrelor May Reduce Subsequent Myocardial Infarction Risk
EP. 7: Adverse Effects in PEGASUS-TIMI 54 Trial
EP. 8: Potential Change in Guidelines for Ticagrelor Therapy